{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:36:33Z","timestamp":1740123393282,"version":"3.37.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>During the alirocumab open-label extension study ODYSSEY OLE (open-label extension; NCT01954394), physicians could adjust alirocumab dosing for enrolled patients, who were diagnosed with heterozygous familial hypercholesterolemia (HeFH) and who had completed previous phase III clinical trials with alirocumab. This post hoc analysis evaluated the differences in physician\u2013patient dosing decisions between the regions of Western Europe, Eastern Europe, North America, and the rest of the world (ROW).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients (<jats:italic>n<\/jats:italic>\u2009=\u2009909) who received starting dose alirocumab 75\u00a0mg every 2\u00a0weeks (Q2W) during ODYSSEY OLE (patients from FH I, FH II, and LONG TERM parent studies) were included. Low-density lipoprotein cholesterol (LDL-C) levels were blinded until week 8; subsequently, LDL-C values were communicated to physicians. From week 12, dose adjustment from 75 to 150\u00a0mg Q2W, or vice versa, was possible.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Mean LDL-C values used for the decision to increase dose from 75 to 150\u00a0mg Q2W were higher in Eastern Europe (3.7\u00a0mmol\/L; 144.0\u00a0mg\/dL) and ROW (3.8\u00a0mmol\/L; 145.2\u00a0mg\/dL) compared with Western Europe (3.1\u00a0mmol\/L; 118.6\u00a0mg\/dL) and North America (3.3\u00a0mmol\/L; 126.6\u00a0mg\/dL). Irrespective of region, the mean LDL-C at the time of decision to maintain at 75\u00a0mg Q2W was approximately 1.8\u00a0mmol\/L (70\u00a0mg\/dL). During ODYSSEY OLE (median treatment duration of 131.7\u00a0weeks), alirocumab was shown to have no unexpected long-term safety concerns.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this OLE study, the observed variations in clinical treatment decisions suggest that physicians may perceive the severity of HeFH and\/or the treatment of HeFH differently depending on their region.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s10557-020-06984-0","type":"journal-article","created":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T03:29:27Z","timestamp":1588562967000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study"],"prefix":"10.1007","volume":"34","author":[{"given":"Gisle","family":"Langslet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Guyton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexia","family":"Letierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garen","family":"Manvelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Farnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"6984_CR1","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J. 2013;34:3478\u201390a.","journal-title":"Eur Heart J"},{"key":"6984_CR2","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","volume":"132","author":"SS Gidding","year":"2015","unstructured":"Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association. Circulation. 2015;132:2167\u201392.","journal-title":"Circulation."},{"key":"6984_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1567-5688(17)30022-3","volume":"26","author":"M Farnier","year":"2017","unstructured":"Farnier M, Civeira F, Descamps O, FH expert working group. How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. Atheroscler Suppl. 2017;26:25\u201335.","journal-title":"Atheroscler Suppl"},{"key":"6984_CR4","doi-asserted-by":"publisher","first-page":"e9220","DOI":"10.1371\/journal.pone.0009220","volume":"5","author":"R Huijgen","year":"2010","unstructured":"Huijgen R, Kindt I, Verhoeven SB, Sijbrands EJ, Vissers MN, Kastelein JJ, et al. Two years after molecular diagnosis of familial hypercholesterolemia: majority on cholesterol-lowering treatment but a minority reaches treatment goal. PLoS One. 2010;5:e9220.","journal-title":"PLoS One"},{"key":"6984_CR5","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37:2999\u20133058.","journal-title":"Eur Heart J"},{"key":"6984_CR6","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","volume":"67","author":"L Perez de Isla","year":"2016","unstructured":"Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muniz O, et al. Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-Year SAFEHEART registry follow-up. J Am Coll Cardiol. 2016;67:1278\u201385.","journal-title":"J Am Coll Cardiol"},{"key":"6984_CR7","first-page":"e1082","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1082\u2013e143.","journal-title":"Circulation."},{"key":"6984_CR8","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1093\/eurheartj\/ehv028","volume":"36","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Cariou B, Blom D, McKenney JM, Lorenzato C, Pordy R, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186\u201394.","journal-title":"Eur Heart J"},{"key":"6984_CR9","first-page":"2996","volume":"36","author":"JJ Kastelein","year":"2015","unstructured":"Kastelein JJ, Ginsberg HN, Langslet G, Hovingh GK, Ceska R, Dufour R, et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur Heart J. 2015;36:2996\u20133003.","journal-title":"Eur Heart J"},{"key":"6984_CR10","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372:1489\u201399.","journal-title":"N Engl J Med"},{"key":"6984_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10557-016-6685-y","volume":"30","author":"HN Ginsberg","year":"2016","unstructured":"Ginsberg HN, Rader DJ, Raal FJ, Guyton JR, Baccara-Dinet MT, Lorenzato C, et al. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia and LDL-C of 160 mg\/dl or higher. Cardiovasc Drugs Ther. 2016;30:473\u201383.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6984_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","volume":"278","author":"M Farnier","year":"2018","unstructured":"Farnier M, Hovingh GK, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, et al. Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis. 2018;278:307\u201314.","journal-title":"Atherosclerosis."},{"key":"6984_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jacl.2018.08.011","volume":"12","author":"GK Hovingh","year":"2018","unstructured":"Hovingh GK, Guyton JR, Langslet G, Dufour R, Baccara-Dinet MT, Din-Bell C, et al. Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. J Clin Lipidol. 2018;12:1463\u201370.","journal-title":"J Clin Lipidol"},{"key":"6984_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","volume":"234","author":"S Beliard","year":"2014","unstructured":"Beliard S, Carreau V, Carrie A, Giral P, Duchene E, Farnier M, et al. Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects. Atherosclerosis. 2014;234:136\u201341.","journal-title":"Atherosclerosis."},{"key":"6984_CR15","doi-asserted-by":"crossref","unstructured":"Writing Committee, Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr., et al. 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2016;68:92\u2013125.","DOI":"10.1016\/j.jacc.2016.03.519"},{"key":"6984_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jacl.2019.01.010","volume":"13","author":"MP Bogsrud","year":"2019","unstructured":"Bogsrud MP, Graesdal A, Johansen D, Langslet G, Hovland A, Arnesen KE, et al. LDL-cholesterol goal achievement, cardiovascular disease, and attributed risk of Lp(a) in a large cohort of predominantly genetically verified familial hypercholesterolemia. J Clin Lipidol. 2019;13:279\u201386.","journal-title":"J Clin Lipidol"},{"key":"6984_CR17","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1093\/eurheartj\/ehx166","volume":"38","author":"C Waldeyer","year":"2017","unstructured":"Waldeyer C, Makarova N, Zeller T, Schnabel RB, Brunner FJ, Jorgensen T, et al. Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium. Eur Heart J. 2017;38:2490\u20138.","journal-title":"Eur Heart J"},{"key":"6984_CR18","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","volume":"63","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, Bairey Merz CN, Lloyd-Jones DM, Blum CB, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014;63:2889\u2013934.","journal-title":"J Am Coll Cardiol"},{"key":"6984_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.cjca.2016.07.510","volume":"32","author":"TJ Anderson","year":"2016","unstructured":"Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian cardiovascular society guidelines for the Management of Dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016;32:1263\u201382.","journal-title":"Can J Cardiol"},{"key":"6984_CR20","unstructured":"NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification. Clinical guideline. 2014:nice.org.uk\/guidance\/cg181 (June 2019)."},{"key":"6984_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5114\/aoms.2017.64712","volume":"13","author":"M Banach","year":"2017","unstructured":"Banach M, Jankowski P, Jozwiak J, Cybulska B, Windak A, Guzik T, et al. PoLA\/CFPiP\/PCS guidelines for the management of dyslipidaemias for family physicians 2016. Arch Med Sci. 2017;13:1\u201345.","journal-title":"Arch Med Sci"},{"key":"6984_CR22","first-page":"1","volume":"15","author":"Joint Committee for Guideline Revision","year":"2018","unstructured":"Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15:1\u201329.","journal-title":"J Geriatr Cardiol"},{"key":"6984_CR23","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s12170-019-0597-x","volume":"13","author":"MA Bartlomiejczyk","year":"2019","unstructured":"Bartlomiejczyk MA, Penson P, Banach M. Worldwide dyslipidemia guidelines. Curr Cardiovasc Risk Rep. 2019;13:2.","journal-title":"Curr Cardiovasc Risk Rep"},{"key":"6984_CR24","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7196\/SAMJ.2018.v108i11.13383","volume":"108","author":"E Klug","year":"2018","unstructured":"Klug E, Raal FJ, Marais AD, Smuts CM, Schamroth C, Jankelow D, et al. South African dyslipidaemia guideline consensus statement: 2018 update a joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). S Afr Med J. 2018;108:973\u20131000.","journal-title":"S Afr Med J"},{"key":"6984_CR25","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","volume":"32","author":"Z Reiner","year":"2011","unstructured":"European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, et al. ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769\u2013818.","journal-title":"Eur Heart J"},{"key":"6984_CR26","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1177\/2047487318777079","volume":"25","author":"N Danchin","year":"2018","unstructured":"Danchin N, Almahmeed W, Al-Rasadi K, Azuri J, Berrah A, Cuneo CA, et al. Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: the International ChoLesterol management Practice Study (ICLPS). Eur J Prev Cardiol. 2018;25:1087\u201394.","journal-title":"Eur J Prev Cardiol"},{"key":"6984_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacl.2019.05.004","volume":"13","author":"DJ Blom","year":"2019","unstructured":"Blom DJ, Almahmeed W, Al-Rasadi K, Azuri J, Daclin V, Kayikcioglu M, et al. Low-density lipoprotein cholesterol goal achievement in patients with familial hyphercholesterolemia in countries outside Western Europe: the International ChoLesterol management Practice Study. J Clin Lipidol. 2019;13:594\u2013600.","journal-title":"J Clin Lipidol"},{"key":"6984_CR28","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1194\/jlr.R072231","volume":"57","author":"R Mehta","year":"2016","unstructured":"Mehta R, Zubiran R, Martagon AJ, Vazquez-Cardenas A, Segura-Kato Y, Tusie-Luna MT, et al. The panorama of familial hypercholesterolemia in Latin America: a systematic review. J Lipid Res. 2016;57:2115\u201329.","journal-title":"J Lipid Res"},{"key":"6984_CR29","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","volume":"209","author":"AH Pijlman","year":"2010","unstructured":"Pijlman AH, Huijgen R, Verhagen SN, Imholz BP, Liem AH, Kastelein JJ, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. Atherosclerosis. 2010;209:189\u201394.","journal-title":"Atherosclerosis."},{"key":"6984_CR30","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"6984_CR31","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"6984_CR32","unstructured":"Sanofi-Aventis U.S. LLC. PRALUENT\u00ae (alirocumab) injection, for subcutaneous use. 2019. http:\/\/products.sanofi.us\/praluent\/praluent.pdf. Accessed Jan 2020."},{"key":"6984_CR33","unstructured":"Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC.\u00a0Praluent summary of product characteristics (EC). 2015. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150923132812\/anx_132812_en.pdf. Accessed Jan 2020."}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-020-06984-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-020-06984-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T20:56:59Z","timestamp":1666472219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-020-06984-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["6984"],"URL":"https:\/\/doi.org\/10.1007\/s10557-020-06984-0","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2020,5,4]]},"assertion":[{"value":"4 May 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Langslet has received speaker and expert witness fees from Sanofi, Amgen, and Boehringer Ingelheim. Professor Hovingh is a holder of a Vidi grant (016.156.445) from the Netherlands Organisation for Scientific Research (NWO) and from Klinkerpad; has received research support from Aegerion, Amgen, and Sanofi; has served as a consultant and received speaker fees from Amgen; Aegerion; Sanofi; Regeneron Pharmaceuticals, Inc.; and Pfizer; and has been employed part-time by Novo Nordisk AS, Copenhagen, Denmark, since April 2019. Professor Guyton has received research support from Sanofi, Regeneron Pharmaceuticals, Inc., Amgen, and Amarin; and has served as a consultant for Amgen, and FH Foundation. Drs. Baccara-Dinet and Letierce are stockholders and employees of Sanofi. Dr. Manvelian is a stockholder and an employee of Regeneron Pharmaceuticals, Inc. Dr. Farnier has received research support from Sanofi\/Regeneron Pharmaceuticals, Inc.; Amgen; and Merck and Co; has served as a consultant for Sanofi\/Regeneron Pharmaceuticals, Inc.; Pfizer; Amgen; Merck and Co; Eli Lilly; AstraZeneca; Kowa; Akcea\/Ionis; Amarin; and Servier; and has received speaker fees from Sanofi\/Regeneron Pharmaceuticals, Inc.; Abbott; Amgen; Merck and Co; Pfizer; and Mylan.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}